Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant + Palonosetron in Pediatric CINV
NCT03204279Phase 2Completed
- Sponsor
- Helsinn
- Start
- Aug 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of netupitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Helsinn. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity at 168 hours, Maximum Plasma Concentration at 168 hours and 1 more. Started Aug 2017; status: completed.
02
Drugs
netupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03204279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204279.